OTLK Outlook Therapeutics Inc

Price (delayed)

$0.8049

Market cap

$97.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.17

Enterprise value

$116.72M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 63
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 0

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME ...

Highlights
The revenue has soared by 62% QoQ
The net income has grown by 41% from the previous quarter
The EPS has plunged by 162% YoY but it has soared by 55% from the previous quarter
The quick ratio has soared by 50% since the previous quarter but it has declined by 10% year-on-year

Key stats

What are the main financial stats of OTLK

OTLK stock price

How has the Outlook Therapeutics stock price performed over time
Intraday
-0.61%
1 week
8.77%
1 month
206.63%
1 year
-57.86%
YTD
-49.06%
QTD
291.11%

Financial performance

How have Outlook Therapeutics's revenue and profit performed over time
Revenue
$333,141
Gross profit
-$1.2M
Operating income
-$60.57M
Net income
-$60.96M
Gross margin
-360.9%
Net margin
-18,297.5%
OTLK's net margin has surged by 63% since the previous quarter
The revenue has soared by 62% QoQ
The net income has grown by 41% from the previous quarter
The gross margin is up by 37% since the previous quarter

Price vs fundamentals

How does OTLK's price correlate with its fundamentals

Growth

What is Outlook Therapeutics's growth rate over time

Valuation

What is Outlook Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
197.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
350.37
The EPS has plunged by 162% YoY but it has soared by 55% from the previous quarter
Outlook Therapeutics's equity has increased by 25% QoQ and by 11% YoY
The revenue has soared by 62% QoQ
The P/S is 38% higher than the last 4 quarters average of 144.6

Efficiency

How efficient is Outlook Therapeutics business performance
The ROS has soared by 63% from the previous quarter
OTLK's return on invested capital has dropped by 52% since the previous quarter
The company's return on assets rose by 43% QoQ

Dividends

What is OTLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OTLK.

Financial health

How did Outlook Therapeutics financials performed over time
OTLK's total assets is 57% smaller than its total liabilities
The current ratio has soared by 54% from the previous quarter but it has contracted by 25% YoY
The quick ratio has soared by 50% since the previous quarter but it has declined by 10% year-on-year
OTLK's debt is 194% greater than its equity
OTLK's debt is down by 26% since the previous quarter and by 18% year-on-year
Outlook Therapeutics's equity has increased by 25% QoQ and by 11% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.